Haematological diseases : nature.com subject feedshttps://www.nature.com/subjects/haematological-diseases.atom2024-03-29T05:15:37+00:00Author Correction: CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancieshttps://www.nature.com/articles/s41467-024-47038-52024-03-27T00:00:00+00:002024-03-27T00:00:00+00:00Yongxian Hu et al.A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndromehttps://www.nature.com/articles/s41409-023-02195-x2024-03-27T00:00:00+00:002024-03-27T00:00:00+00:00Ray Mun Koo et al.Brain network hypersensitivity underlies pain crises in sickle cell diseasehttps://www.nature.com/articles/s41598-024-57473-52024-03-27T00:00:00+00:002024-03-27T00:00:00+00:00Pangyu Joo et al.Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patientshttps://www.nature.com/articles/s41375-024-02230-w2024-03-27T00:00:00+00:002024-03-27T00:00:00+00:00Shai Shimony et al.A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirementshttps://www.nature.com/articles/s41408-024-01025-72024-03-26T00:00:00+00:002024-03-26T00:00:00+00:00Massimiliano Bonifacio et al.Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?https://www.nature.com/articles/s41375-024-02229-32024-03-26T00:00:00+00:002024-03-26T00:00:00+00:00Hagop Kantarjian et al.Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapyhttps://www.nature.com/articles/s41375-024-02208-82024-03-26T00:00:00+00:002024-03-26T00:00:00+00:00Eduardo Sabino de Camargo Magalhães et al.How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?https://www.nature.com/articles/s41408-024-00996-x2024-03-26T00:00:00+00:002024-03-26T00:00:00+00:00Ing Soo Tiong et al.EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantationhttps://www.nature.com/articles/s41409-024-02270-x2024-03-23T00:00:00+00:002024-03-23T00:00:00+00:00Carles Tolosa-Ridao et al.Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysishttps://www.nature.com/articles/s41408-024-01034-62024-03-22T00:00:00+00:002024-03-22T00:00:00+00:00Fieke W. Hoff et al.The Eμ-Ret mouse is a novel model of hyperdiploid B-cell acute lymphoblastic leukemiahttps://www.nature.com/articles/s41375-024-02221-x2024-03-22T00:00:00+00:002024-03-22T00:00:00+00:00Ali Farrokhi et al.Clonal hematopoiesis and its impact on the aging osteo-hematopoietic nichehttps://www.nature.com/articles/s41375-024-02226-62024-03-21T00:00:00+00:002024-03-21T00:00:00+00:00Susann Winter et al.Transplantation for myelofibrosis patients in the ruxolitinib era: a registry study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulairehttps://www.nature.com/articles/s41409-024-02268-52024-03-21T00:00:00+00:002024-03-21T00:00:00+00:00Sara Villar et al.Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligencehttps://www.nature.com/articles/s41746-024-01076-x2024-03-20T00:00:00+00:002024-03-20T00:00:00+00:00Jan-Niklas Eckardt et al.Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplanthttps://www.nature.com/articles/s41408-024-01028-42024-03-19T00:00:00+00:002024-03-19T00:00:00+00:00Ayalew Tefferi et al.Treatment and survival for patients with localized primary ocular adnexal extranodal marginal zone lymphomahttps://www.nature.com/articles/s41375-024-02227-52024-03-19T00:00:00+00:002024-03-19T00:00:00+00:00Lin-Rui Gao et al.Impact of anemia requiring transfusion or erythropoiesis-stimulating agents on new-onset cardiovascular events and mortality after continuous renal replacement therapyhttps://www.nature.com/articles/s41598-024-56772-12024-03-19T00:00:00+00:002024-03-19T00:00:00+00:00Junseok Jeon et al.Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMThttps://www.nature.com/articles/s41409-024-02256-92024-03-19T00:00:00+00:002024-03-19T00:00:00+00:00Romain Guièze et al.The estimated mediating roles of anemia-related variables in the association between kidney function and mortality: a National Health and Nutrition Examination Survey (NHANES) studyhttps://www.nature.com/articles/s41598-024-56877-72024-03-19T00:00:00+00:002024-03-19T00:00:00+00:00Yae Hyun Kim et al.Genetically determined telomere length and risk for haematologic diseases: results from large prospective cohorts and Mendelian Randomization analysishttps://www.nature.com/articles/s41408-024-01035-52024-03-18T00:00:00+00:002024-03-18T00:00:00+00:00Yang Li et al.Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approvalhttps://www.nature.com/articles/s41408-024-01029-32024-03-18T00:00:00+00:002024-03-18T00:00:00+00:00Ayalew Tefferi et al.Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?https://www.nature.com/articles/s41408-024-01027-52024-03-18T00:00:00+00:002024-03-18T00:00:00+00:00Mostafa Abdallah et al.Long term results of a prospective multicenter obervational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study)https://www.nature.com/articles/s41409-024-02264-92024-03-16T00:00:00+00:002024-03-16T00:00:00+00:00Jürgen Finke et al.Risk factors for acute chest syndrome among children with sickle cell anemia hospitalized for vaso-occlusive criseshttps://www.nature.com/articles/s41598-023-48527-12024-03-12T00:00:00+00:002024-03-12T00:00:00+00:00Faisal A. Alghamdi et al.Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALFhttps://www.nature.com/articles/s41375-024-02215-92024-03-12T00:00:00+00:002024-03-12T00:00:00+00:00Daniela Žáčková et al.Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committeehttps://www.nature.com/articles/s41375-024-02182-12024-03-12T00:00:00+00:002024-03-12T00:00:00+00:00Donal P. McLornan et al.Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Grouphttps://www.nature.com/articles/s41409-024-02260-z2024-03-09T00:00:00+00:002024-03-09T00:00:00+00:00F. Fazio et al.Myelodysplastic neoplasms dissected into indolent, leukaemic and unfavourable subtypes by computational clustering of haematopoietic stem and progenitor cellshttps://www.nature.com/articles/s41375-024-02203-z2024-03-08T00:00:00+00:002024-03-08T00:00:00+00:00Margot F. van Spronsen et al.Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE studyhttps://www.nature.com/articles/s41375-024-02213-x2024-03-08T00:00:00+00:002024-03-08T00:00:00+00:00Annalisa Chiappella et al.Late-onset pulmonary complications following allogeneic hematopoietic cell transplantation in pediatric patients: a prospective multicenter studyhttps://www.nature.com/articles/s41409-024-02258-72024-03-07T00:00:00+00:002024-03-07T00:00:00+00:00Véronique Houdouin et al.